142 related articles for article (PubMed ID: 23123690)
1. Clinical experience of dose conversion ratios between 2 botulinum toxin products in the treatment of cervical dystonia.
Rystedt A; Nyholm D; Naver H
Clin Neuropharmacol; 2012; 35(6):278-82. PubMed ID: 23123690
[TBL] [Abstract][Full Text] [Related]
2. Safety, effectiveness, and duration of effect of BOTOX after switching from Dysport for blepharospasm, cervical dystonia, and hemifacial spasm dystonia, and hemifacial spasm.
Bihari K
Curr Med Res Opin; 2005 Mar; 21(3):433-8. PubMed ID: 15811212
[TBL] [Abstract][Full Text] [Related]
3. Comparison of botulinum neurotoxin preparations for the treatment of cervical dystonia.
Chapman MA; Barron R; Tanis DC; Gill CE; Charles PD
Clin Ther; 2007 Jul; 29(7):1325-37. PubMed ID: 17825685
[TBL] [Abstract][Full Text] [Related]
4. A Comparison of Botox 100 U/mL and Dysport 100 U/mL Using Dose Conversion Ratio 1: 3 and 1: 1.7 in the Treatment of Cervical Dystonia: A Double-Blind, Randomized, Crossover Trial.
Rystedt A; Zetterberg L; Burman J; Nyholm D; Johansson A
Clin Neuropharmacol; 2015; 38(5):170-6. PubMed ID: 26366966
[TBL] [Abstract][Full Text] [Related]
5. Retrospective evaluation of the dose of Dysport and BOTOX in the management of cervical dystonia and blepharospasm: the REAL DOSE study.
Marchetti A; Magar R; Findley L; Larsen JP; Pirtosek Z; Růzicka E; Jech R; Sławek J; Ahmed F
Mov Disord; 2005 Aug; 20(8):937-44. PubMed ID: 15810022
[TBL] [Abstract][Full Text] [Related]
6. Respective potencies of Botox and Dysport: a double blind, randomised, crossover study in cervical dystonia.
Ranoux D; Gury C; Fondarai J; Mas JL; Zuber M
J Neurol Neurosurg Psychiatry; 2002 Apr; 72(4):459-62. PubMed ID: 11909903
[TBL] [Abstract][Full Text] [Related]
7. What is the optimal dose of botulinum toxin A in the treatment of cervical dystonia? Results of a double blind, placebo controlled, dose ranging study using Dysport. German Dystonia Study Group.
Poewe W; Deuschl G; Nebe A; Feifel E; Wissel J; Benecke R; Kessler KR; Ceballos-Baumann AO; Ohly A; Oertel W; Künig G
J Neurol Neurosurg Psychiatry; 1998 Jan; 64(1):13-7. PubMed ID: 9436721
[TBL] [Abstract][Full Text] [Related]
8. A double blind, randomised, parallel group study to investigate the dose equivalence of Dysport and Botox in the treatment of cervical dystonia.
Odergren T; Hjaltason H; Kaakkola S; Solders G; Hanko J; Fehling C; Marttila RJ; Lundh H; Gedin S; Westergren I; Richardson A; Dott C; Cohen H
J Neurol Neurosurg Psychiatry; 1998 Jan; 64(1):6-12. PubMed ID: 9436720
[TBL] [Abstract][Full Text] [Related]
9. Dysport and Botox at a ratio of 2.5:1 units in cervical dystonia: a double-blind, randomized study.
Yun JY; Kim JW; Kim HT; Chung SJ; Kim JM; Cho JW; Lee JY; Lee HN; You S; Oh E; Jeong H; Kim YE; Kim HJ; Lee WY; Jeon BS
Mov Disord; 2015 Feb; 30(2):206-13. PubMed ID: 25476727
[TBL] [Abstract][Full Text] [Related]
10. Dysport (botulinum toxin type A) in routine therapeutic usage: a telephone needs assessment survey of European physicians to evaluate current awareness and adherence to product labeling changes.
Hubble J; Schwab J; Hubert C; Abbott CC
Clin Neuropharmacol; 2013; 36(4):122-7. PubMed ID: 23783005
[TBL] [Abstract][Full Text] [Related]
11. A long-term follow-up of botulinum toxin A in cervical dystonia.
Mohammadi B; Buhr N; Bigalke H; Krampfl K; Dengler R; Kollewe K
Neurol Res; 2009 Jun; 31(5):463-6. PubMed ID: 19278576
[TBL] [Abstract][Full Text] [Related]
12. DYSBOT: a single-blind, randomized parallel study to determine whether any differences can be detected in the efficacy and tolerability of two formulations of botulinum toxin type A--Dysport and Botox--assuming a ratio of 4:1.
Sampaio C; Ferreira JJ; Simões F; Rosas MJ; Magalhães M; Correia AP; Bastos-Lima A; Martins R; Castro-Caldas A
Mov Disord; 1997 Nov; 12(6):1013-8. PubMed ID: 9399229
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study.
Truong D; Duane DD; Jankovic J; Singer C; Seeberger LC; Comella CL; Lew MF; Rodnitzky RL; Danisi FO; Sutton JP; Charles PD; Hauser RA; Sheean GL
Mov Disord; 2005 Jul; 20(7):783-91. PubMed ID: 15736159
[TBL] [Abstract][Full Text] [Related]
14. Same-patient prospective comparison of Botox versus Dysport for the treatment of primary axillary hyperhidrosis and review of literature.
Vergilis-Kalner IJ
J Drugs Dermatol; 2011 Sep; 10(9):1013-5. PubMed ID: 22052270
[TBL] [Abstract][Full Text] [Related]
15. Biological activity of two botulinum toxin type A complexes (Dysport and Botox) in volunteers: a double-blind, randomized, dose-ranging study.
Wohlfarth K; Schwandt I; Wegner F; Jürgens T; Gelbrich G; Wagner A; Bogdahn U; Schulte-Mattler W
J Neurol; 2008 Dec; 255(12):1932-9. PubMed ID: 18854916
[TBL] [Abstract][Full Text] [Related]
16. [Botulinum toxin treatment of hip adductor spasticity in multiple sclerosis].
Wissel J; Entner T
Wien Klin Wochenschr; 2001; 113 Suppl 4():20-4. PubMed ID: 15506048
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic properties of different formulations of botulinum neurotoxin type A.
Wohlfarth K; Kampe K; Bigalke H
Mov Disord; 2004 Mar; 19 Suppl 8():S65-7. PubMed ID: 15027057
[TBL] [Abstract][Full Text] [Related]
18. Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia.
Comella CL; Jankovic J; Shannon KM; Tsui J; Swenson M; Leurgans S; Fan W;
Neurology; 2005 Nov; 65(9):1423-9. PubMed ID: 16275831
[TBL] [Abstract][Full Text] [Related]
19. Concurrent onabotulinumtoxinA treatment of cervical dystonia and concomitant migraine.
Winner PK; Sadowsky CH; Martinez WC; Zuniga JA; Poulette A
Headache; 2012 Sep; 52(8):1219-25. PubMed ID: 22607530
[TBL] [Abstract][Full Text] [Related]
20. Effect of botulinum toxin concentration on reduction in sweating: a randomized, double-blind study.
Rystedt A; Karlqvist M; Bertilsson M; Naver H; Swartling C
Acta Derm Venereol; 2013 Nov; 93(6):674-8. PubMed ID: 23694974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
